Conclusion-This pilot study provides encouraging evidence of the efficacy and safety of a 3 day course of 2% clindamycin cream in bacterial vaginosis.
Introduction
Bacterial vaginosis (BV) is a common condition which in 1990 accounted for 33% of all cases of vaginal infections seen in genitourinary medicine (GUM) clinics in England.' Just how the condition is initiated remains a mystery. However, there is a shift in the vaginal flora that is, replacement of the normal Lactobacillus-predominant vaginal flora by vast numbers of other organisms, especially, Gardnerella vaginalis, obligate anaerobes and Mycoplasma hominis.
Currently metronidazole is considered the drug of choice. However, the condition often recurs for reasons yet unknown. Other drawbacks of metronidazole include its side effects and uncertainty about the effects of metronidazole on the foetus. The recent reports of association of BV with preterm birth,2 low birth weight, postpartum endometritis3 and pelvic infection4 have also highlighted the need for alternative treatment, especially in pregnant women.
Clindamycin has excellent activity against anaerobic bacteria5 and has been found to be effective in the treatment of BV when given orally in doses of 300 mg twice daily for 1 week6 and when applied intravaginally as a 2% cream twice daily for 5 days7 or once daily for 7 days. After obtaining written informed consent, the patients were assigned to one of the two treatment groups in a random, double blind, 1:1 fashion. Each patient received a tube containing either 20g 2% clindamycin vaginal cream or 20g matching placebo cream and three disposable applicators. They were instructed to insert 5g of cream high into the vagina at bedtime for three consecutive nights and to return any unused cream at the next clinic attendance. The patients were to be assessed at 7 days (Visit I) and 28 days (Visit II) after the start of treatment.
The patients were requested to abstain from sexual intercourse and to avoid prolonged soaking in a bath until the first followup at day 7 (Visit I), after treatment.
At Visit I, any new symptoms, adverse events, sexual history, administration of medication and concurrent use of other agents was noted. Thereafter, clinical examination and base line tests were repeated. The second follow-up at 28 days (Visit II) after completion of therapy included a similar assessment.
The patients were considered to be evaluable at Visit I if they used the medication as described in the protocol, and had not received any other antibiotics or antifungals (topical or systemic), and had not menstruated within 72 hours of the last application of the protocol therapy. The Clindamycin 12   2  3  17  Placebo   --3  3 weight, menstrual cycle, parity, number of abortions, bowel habits, history of previous infections or previous episodes of BV and methods of contraception, did not yield any significant differences. Table 2 lists the treatment outcomes at Visit 1 when 44 patients were evaluable. The overall success together with improvement rate was 96.6% (22/23) with clindamycin and this was highly significant when compared with the placebo group (p < 0.001). Symptomatic candidal vulvovaginitis requiring treatment was seen in one patient in the clindamycin group. Diarrhoea was reported by one patient in each group. However, both the patients with diarrhoea recovered without any residual effects and did not need any treatment.
In the Clindamycin Group, C trachomatis was isolated from the endocervical swabs of three patients who were accordingly treated for chlamydia infection (with tetracycline) at the follow-up Visit I. The one patient with persistent BV received a course of metronidazole tablets. A further two patients defaulted. After excluding all these patients, 17 were evaluable at follow-up Visit II. Success or improvement was noted in 14 (82A4%) while BV recurred in three (table 3) . Of the three patients treated for chlamydia infection and one retreated for persistent BV at the followup Visit I, three (including the one retreated for persistent BV) returned at the follow-up Visit II and all were considered cured.
In the Placebo Group, of the 20 with persistent BV, 16 had symptoms of whom five were also found to be infected with C trachomatis. These five cases were, therefore, treated for chlamydia (with tetracycline) as well as persistent BV (with metronidazole) at follow-up Visit I. All of the remaining 11 received a course of metronidazole tablets. A further two patients (including one success at Visit I) defaulted. After excluding all these patients, only three patients (asymptomatic at Visit I) were evaluable at follow-up Visit II, and they had by then begun to re-experience malodorous vaginal discharge. Results of wet film and gram stain of the vaginal material were once again consistent with the presence of BV (table 3) . Of the 16 patients retreated at the follow-up Visit I, eight returned at the follow-up Visit II, seven were considered cured and one patient who had received tetracycline and metronidazole, although asymptomatic, showed evidence of BV.
Discussion
Various treatmnent regimens, both oral and topical, have been used for BV. At present the United States Center for Disease Control recommends metronidazole, 500mg orally twice daily for 1 week.'0 (Because of metronidazole formulation, the dose in Great Britain is 400mg, twice daily). However, the possibility of side effects necessitates search for an alternative to metronidazole, especially for use in early pregnancy.
Clindamycin has been shown to be effective in the treatment of this condition. In a study by Greaves et The present study demonstrates that a 3 day course of 5 grammes of 2% clindamycin cream applied vaginally once daily has similar cure rates as a five or a seven day course referred to above. It is also comparable with treatment with metronidazole, and, pending further proof of its efficacy and its safety in pregnancy, is likely to become the preferred treatment in pregnant women. No serious adverse side effects were noted with its use. Other advantages are topical treatment and possibly better patient compliance due to the short course of treatment. 
